Literature DB >> 12597429

Evaluation of large-sized brains for neurotoxic endpoints.

Robert H Garman1.   

Abstract

Sampling of large-sized brains (eg, dog, primate) for microscopic examination is frequently inadequate to detect localized neurotoxic injury. Furthermore, the examination of H&E-stained sections alone will often be insufficient for the detection of subtle neuropathogic alteration. It is imperative for any pathologist evaluating brain sections to have knowledge of microscopic neuroanatomy and to also have some understanding of basic neurochemistry. When a focus of degeneration is detected within the brain, the pathologist needs to ascertain not only the specific anatomic location of this focus but also the neuroanatomic regions that project to and receive output from the injured focus. Because of the complexity of brain circuitry and the fact that the brain contains many distinctive neuron populations, many more brain sections are required for adequate microscopic evaluation than for any other body organ. Deciding which and how many areas should be examined, microscopically, from a large size brain is often problematic. Although any sampling protocol will be influenced by what is known about the test chemical, it has been well established that certain regions of the brain (eg, hippocampus and other components of the limbic system, basal ganglia, Purkinje neurons) are more susceptible than others to a variety of physical, metabolic, and chemical insults. Knowledge of these regional sensitivities will assist in guiding the pathologist in the development of an adequate sampling protocol.

Entities:  

Mesh:

Year:  2003        PMID: 12597429     DOI: 10.1080/01926230390174913

Source DB:  PubMed          Journal:  Toxicol Pathol        ISSN: 0192-6233            Impact factor:   1.902


  5 in total

1.  AGT-181: expression in CHO cells and pharmacokinetics, safety, and plasma iduronidase enzyme activity in Rhesus monkeys.

Authors:  Ruben J Boado; Eric K-W Hui; Jeff Zhiqiang Lu; William M Pardridge
Journal:  J Biotechnol       Date:  2009-09-06       Impact factor: 3.307

2.  IgG-enzyme fusion protein: pharmacokinetics and anti-drug antibody response in rhesus monkeys.

Authors:  Ruben J Boado; Eric Ka-Wai Hui; Jeff Zhiqiang Lu; William M Pardridge
Journal:  Bioconjug Chem       Date:  2012-12-31       Impact factor: 4.774

3.  Insulin receptor antibody-iduronate 2-sulfatase fusion protein: pharmacokinetics, anti-drug antibody, and safety pharmacology in Rhesus monkeys.

Authors:  Ruben J Boado; Eric Ka-Wai Hui; Jeff Zhiqiang Lu; William M Pardridge
Journal:  Biotechnol Bioeng       Date:  2014-08-05       Impact factor: 4.530

4.  Cognitive Function, Progression of Age-related Behavioral Changes, Biomarkers, and Survival in Dogs More Than 8 Years Old.

Authors:  T Schütt; N Toft; M Berendt
Journal:  J Vet Intern Med       Date:  2015-10-13       Impact factor: 3.333

5.  Pharmacokinetics and safety in rhesus monkeys of a monoclonal antibody-GDNF fusion protein for targeted blood-brain barrier delivery.

Authors:  William M Pardridge; Ruben J Boado
Journal:  Pharm Res       Date:  2009-07-17       Impact factor: 4.200

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.